AstraZeneca’s global biologics R&D arm MedImmune and the University of Cambridge have entered into a three-year oncology research collaboration in order to advance cancer research by using imaging technologies to measure key biologic changes within growing tumors.
{iframe}http://contractresearch.pharmaceutical-business-review.com/news/medimmune-university-of-cambridge-enter-into-oncology-research-collaboration-130314{/iframe}